Jeffrey B. Locke, PhD

Director, Microbiology
Cidara Therapeutics, Inc.

Disclosure: Cidara Therapeutics, Inc. (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 162 - CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models

  Oral Abstract